Deborah Enting

2.0k total citations
42 papers, 374 citations indexed

About

Deborah Enting is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Deborah Enting has authored 42 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 21 papers in Surgery and 14 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Deborah Enting's work include Bladder and Urothelial Cancer Treatments (20 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Urinary and Genital Oncology Studies (6 papers). Deborah Enting is often cited by papers focused on Bladder and Urothelial Cancer Treatments (20 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Urinary and Genital Oncology Studies (6 papers). Deborah Enting collaborates with scholars based in United Kingdom, Sweden and Canada. Deborah Enting's co-authors include Magdalene Joseph, Mieke Van Hemelrijck, Beth Russell, Rajesh Nair, Sarah Rudman, Gincy George, Yin Wu, Simon Chowdhury, Cecilia Bosco and Charlotte Moss and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Deborah Enting

38 papers receiving 369 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Deborah Enting United Kingdom 9 203 167 87 74 68 42 374
Chris Labaki United States 12 69 0.3× 152 0.9× 127 1.5× 81 1.1× 39 0.6× 56 366
Rick Bangs United States 11 251 1.2× 89 0.5× 83 1.0× 54 0.7× 16 0.2× 31 382
Rossella Di Trolio Italy 13 82 0.4× 201 1.2× 42 0.5× 57 0.8× 62 0.9× 24 422
H Maartmann-Moe Norway 12 199 1.0× 85 0.5× 124 1.4× 52 0.7× 37 0.5× 29 412
Junqiang Tian China 11 135 0.7× 83 0.5× 133 1.5× 136 1.8× 56 0.8× 40 452
Marcus J. Daniels United States 10 280 1.4× 104 0.6× 57 0.7× 90 1.2× 48 0.7× 18 417
Saad Aldousari Kuwait 10 216 1.1× 53 0.3× 91 1.0× 59 0.8× 10 0.1× 27 341
Hannah Christina Puhr Austria 9 82 0.4× 199 1.2× 95 1.1× 55 0.7× 63 0.9× 30 340
Anshuma Bansal India 8 108 0.5× 73 0.4× 41 0.5× 47 0.6× 17 0.3× 29 312
Aurélia Meurisse France 12 121 0.6× 250 1.5× 157 1.8× 49 0.7× 36 0.5× 48 429

Countries citing papers authored by Deborah Enting

Since Specialization
Citations

This map shows the geographic impact of Deborah Enting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Enting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Enting more than expected).

Fields of papers citing papers by Deborah Enting

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Enting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Enting. The network helps show where Deborah Enting may publish in the future.

Co-authorship network of co-authors of Deborah Enting

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Enting. A scholar is included among the top collaborators of Deborah Enting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Enting. Deborah Enting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Galsky, Matthew D., Dean F. Bajorin, Yoshihiko Tomita, et al.. (2025). Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial. Nature Medicine. 31(9). 3062–3073.
2.
Howard, Lauren E., Terry Hyslop, Karen A. Autio, et al.. (2025). Relationship between undetectable PSA nadir and outcomes for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in IRONMAN, the International Registry for Men with Advanced Prostate Cancer.. Journal of Clinical Oncology. 43(5_suppl). 65–65. 1 indexed citations
3.
Watson, Verity, Rajesh Nair, Deborah Enting, et al.. (2024). Treatment preferences of patients with muscle invasive bladder cancer: A discrete choice experiment. SHILAP Revista de lepidopterología. 5(11). 1173–1182.
4.
Jones, Robert J., Simon J. Crabb, Mark Linch, et al.. (2024). Systemic anticancer therapy for urothelial carcinoma: UK oncologists’ perspective. British Journal of Cancer. 130(6). 897–907. 12 indexed citations
5.
6.
Sanderson, Benjamin M., Deborah Enting, Caterina Aversa, et al.. (2022). Using Real-world Data to Define a Validated Nomogram for Advanced Bladder Cancer Patients Who Respond to Immunotherapy. Clinical Oncology. 34(10). 642–652. 5 indexed citations
7.
Crabb, Simon J., Sarah Danson, James W.F. Catto, et al.. (2021). Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). Clinical Cancer Research. 27(7). 1882–1892. 17 indexed citations
8.
Ting, Jonathan Y., Charlotte Moss, Beth Russell, et al.. (2021). COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. Cancers. 13(14). 3573–3573. 37 indexed citations
9.
Fox, Louis, Charlotte Moss, Gincy George, et al.. (2021). Is there a role for physical activity when treating patients with cancer with immune checkpoint inhibitors? Protocol for a scoping review. BMJ Open. 11(10). e046052–e046052. 1 indexed citations
10.
Rammant, Elke, Gincy George, Beth Russell, et al.. (2021). The incidence and prevalence of upper tract urothelial carcinoma: a systematic review. BMC Urology. 21(1). 110–110. 40 indexed citations
11.
Rammant, Elke, Deborah Enting, Richard T. Bryan, et al.. (2021). The need for supportive mental wellbeing interventions in bladder cancer patients: A systematic review of the literature. PLoS ONE. 16(1). e0243136–e0243136. 7 indexed citations
12.
Aversa, Caterina, Arighno Das, Deborah Enting, et al.. (2020). 765P Predicting survival in urothelial cancer patients after immunotherapy using real-world data. Annals of Oncology. 31. S590–S590. 3 indexed citations
13.
Häggström, Christel, Deborah Enting, Muhammad Shamim Khan, et al.. (2020). Unmet needs in sexual health in bladder cancer patients: a systematic review of the evidence. BMC Urology. 20(1). 64–64. 24 indexed citations
14.
Wylie, Harriet, Fidelma Cahill, Aida Santaolalla, et al.. (2019). Graham Roberts Study protocol: first ‘trials within cohort study’ for bladder cancer. BMJ Open. 9(9). e029468–e029468. 5 indexed citations
15.
Joseph, Magdalene & Deborah Enting. (2019). Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications. Frontiers in Oncology. 9. 1270–1270. 89 indexed citations
16.
Devlies, Wout, Aida Santaolalla, Fidelma Cahill, et al.. (2017). King’s Health Partners’ Prostate Cancer Biobank (KHP PCaBB). BMC Cancer. 17(1). 784–784. 11 indexed citations
17.
Young, Thomas W., et al.. (2017). Current management of advanced bladder cancer. Trends in Urology & Men s Health. 8(6). 8–12. 4 indexed citations
18.
19.
Enting, Deborah, Tjip S. van der Werf, T.R. Prins, et al.. (2004). Massale hemoptoë : eerste opvang, diagnostiek en behandeling. Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank. 148(32). 1582–1586. 3 indexed citations
20.
Enting, Deborah, Siebrig Schokker, Eric J. Duiverman, & Thys van der Molen. (2003). The effectiveness of inhaled corticosteroid therapy in preschool children with asthma: a systematic review of the literature. Primary Care Respiratory Journal. 12(2). 52–57. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chris Labaki Breakdown of academic impact, for papers by Rick Bangs Breakdown of academic impact, for papers by Rossella Di Trolio Breakdown of academic impact, for papers by H Maartmann-Moe Breakdown of academic impact, for papers by Junqiang Tian Breakdown of academic impact, for papers by Marcus J. Daniels Breakdown of academic impact, for papers by Saad Aldousari Breakdown of academic impact, for papers by Hannah Christina Puhr Breakdown of academic impact, for papers by Anshuma Bansal Breakdown of academic impact, for papers by Aurélia Meurisse
Rankless by CCL
2026